Effect of Addition of Single Dose of Oral Montelukast to Standard Treatment in Acute Asthma in Preschool Children.

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if adding single dose of oral montelukast to the standard treatment of systemic glucocorticoids plus short acting beta-2 agonist for treatment of acute wheezing provide additional clinical benefit in the emergency room.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kecioren Education and Training Hospital
• Treatments: Albuterol; Glucocorticoids; Montelukast

Criteria

Inclusion Criteria:

• 6 months to 6 years of age

• With at least three episodes of wheezing in the previous 12 months

• Who presented to the ED with a moderate to severe wheezing episode (defined as a Pulmonary Index Score [PIS] of 7 to 13

Exclusion Criteria:

• Patients who were receiving more than 400 mcg of inhaled budesonide or equivalent per day

• Who had any change in their dose of ICSs in the past 2 months

• Who had taken systemic corticosteroid within 1 months

• Patients who have concurrent pneumonia, croup or suspected foreign body aspiration, a history of cystic fibrosis, bronchopulmonary dysplasia, bronchiolitis obliterans, congenital heart disease, liver or renal disease,sickle cell anemia or immune deficiency were excluded.